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Sequential isolatesTuberculosis (TB) is caused by Mycobacterium tuberculosis (MTB) and the disease has
remained a major health problem in most of the developing countries, particularly after
the emergence of multidrug-resistant TB (MDR-TB). The MDR-TB is an intriguing subject
and very little is known about the in vivo processes which take place during the acquisition
of MDR. This study describes a unique case of pulmonary TB (PTB) fromwhich four sequen-
tial isolates of MTB could be isolated while the patient was on anti-tubercular treatment.
The first baseline isolate was sensitive to all drugs, but the subsequent three isolates
acquired resistance to multiple drugs and finally the patient died after 27 months post-
diagnosis when his fourth isolate became resistant to isoniazid, rifampicin, ethambutol
and kanamycin. All sequential cultures were identified as MTB using conventional and
molecular methods, including 16s RNA sequencing and the spoligotyping. Spoligotyping
followed by comparison with SITVITWEB database revealed that all the isolates belonged
to the family of the Central Asian Strain Delhi (CAS1_Delhi, ST26) genotype, and no cross
or mixed infections were observed. The drug resistance was further characterized at the
molecular level by sequencing the target genes (katG, inhA, rpoB, embB, eis promoter region
and rrs). The results revealed mutated alleles associated with resistance to the respective
drugs. This unique case indicates that it is possible to isolate MTB during treatment if
the strain is acquiring resistance. The data presented from four sequential isolates provides
an insight into what sequential genetic and proteomic changes occur in the bacteria during
the in vivo acquisition of MDR.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction new cases and more than 1.4 million deaths annually [1].Mycobacterium tuberculosis (MTB) is the most successful hu-
man pathogen worldwide causing an estimated 8.7 millionIndia has the highest estimated burden of tuberculosis (TB)
in the world, accounting for 26% of all TB cases worldwide.
The emergence of multidrug-resistant (MDR) strains of MTBved.
dicine, All
ia.
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infectious diseases incurable. These drug-resistant strains
are more infectious by virtue of their high transmissibility
in the population [2]. There are several genotypes of MTB.
MTB CAS1_Delhi lineage was first identified in Delhi region
but now it is an emerging pathogen in several areas of the
world, predominantly in South East Asian Countries. It be-
longs to the Spoligotype International Types (SIT) 26, 25, 141,
381, 1327, 1343 and 1344 CAS1_Delhi type (ST 26), and is
highly prevalent in the Indian subcontinent [3,4]. In Europe
and Australia, these strains were often found to be associated
with migrants from South Asia [5]. The lineage, however, is
not considered to be more prone to resistance, as is the Bei-
jing strain. When resistant, mutations in the rpoB, katG genes
are more frequent in these isolates as compared with non-
CAS_Delhi isolates [6]. It is also reported that an increasing
frequency of drug resistance observed in the CAS1_Delhi
sub-lineage isolates was not linked to the patients’ history
of previous anti-TB treatment [6].
This study describes a unique case of four sequential iso-
lations of MTB CAS1_Delhi genotype from a 22-year-old male
patient from Delhi, India, and summarizes the data on their
genotypes, drug resistance and possible evolution of MDR-
TB from a sensitive strain of MTB.
Materials and methods
The patient and MTB isolates
A 22-year-old male patient was diagnosed with pulmonary TB
on the basis of clinical and radiological findings, and sputum
samples were referred from designated microscopy and DOTS
center to the Tuberculosis Laboratory of the Clinical Microbi-
ology and Molecular Medicine Division, All India Institute of
Medical Sciences, New Delhi, India, for culture and drug sus-
ceptibility testing. The patient was prescribed with category I
anti-tubercular treatment (ATT) under directly observed treat-
ment-short course (DOTS) program. The treatment comprised
of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and
ethambutol (EMB), also known as category I treatment as
per revised national TB control program (RNTCP), an initiative
of the Government of India. During the intensive phase of
DOTS, the four drugs are administered for two months, fol-
lowed by four months of treatment with only two (INH and
RIF) drugs.
However, this patient did not follow the regimen, and he
had several interruptions in the treatment, particularly after
the intensive phase when his general condition improved
and he became asymptomatic. Several sputum samples were
collected during the follow-up period of treatment and sub-
jected to BACTEC-MGIT-960 culture isolation. The base line
culture was positive, and the isolate was identified as MTB
by conventional phenotypic characteristics and confirmed
by an in-house polymerase chain reaction (PCR) method [7].
This culture was labeled as isolate A. After three months of
cessation of treatment (6 + 3 = 9 month, Fig. 1), his condition
again deteriorated and his sputum sample was again positive
for MTB. This second culture was labeled as isolate B. He was
again prescribed with INH, RIF, PZA, EMB and streptomycin(STR). This regimen is known as category II as per the RNTCP,
India guidelines. Within two months, his clinical condition
again improved, but after a gap of four months, his symptoms
reappeared. His sputumwas again culture positive which was
labeled as isolate C. The patient was once again prescribed
with the same treatment for another 12 months, but this time
also he stopped treatment after six months. After that, his
condition further deteriorated and he died of disseminated
disease. By this time 27 months had elapsed (Fig. 1). Before
his death, a fourth isolation was made from his sputum sam-
ple and labeled as isolate D.
All the four clinical isolates (A, B, C and D) were identified
as MTB using standard protocols followed in our laboratory,
which is accredited for culture, drug susceptibility and line
probe assay [7,8] and also by 16s RNA gene sequencing. The
anti-mycobacterial drug susceptibility testing was performed
on all the isolates by BACTEC-MGIT-960 (Becton Dickinson,
Microbiology Systems, Sparks, MD), singly as well as in pairs.
To determine the minimum inhibitory concentration (MIC),
tetrazolium microplate assay (TEMA) and proportional meth-
od using Middlebrook 7H10 (Difco, Detroit, MI, USA) agar
plates were used against first-line drugs. In proportional
method the medium contained STR (2.0 lg/ml), INH (0.2 lg/
ml), RIF (1.0 lg/ml), and EMB (6.0 lg/ml) [7,9,10].
From all cultures, DNA was extracted and subjected to
spoligotyping using a commercial kit (Ocimum Biosolutions,
India) as per the manufacturer’s instructions [11], and isolates
were identified using the international SITVITWEB database
[12,13]. Further, 24-loci MIRU-VNTR was performed by PCR
amplification of individual loci using specific primers as de-
scribed previously [14]. The sequencing of 16sRNA for the
rpoB, inhA, katG, embB, eis and rrs gene targets was done using
the primers as described elsewhere [6,15–18].
Results and discussion
Isolates, resistance pattern and gene mutations
A 22-year-old male patient from Delhi was suspected of suf-
fering from pulmonary TB (PTB) based on clinical history
(cough, fever, chest pain, weight loss and loss of appetite),
tuberculin skin test (16 mm) and chest X-ray done in AIIMS
hospital. The chest X-ray showed bilateral cavitary lesions.
The patient had a family history of contact with his brother
who was a smear-positive case and who died of TB a few
years ago. However, no isolation from his brother’s samples
was attempted, as it was not required to culture the samples
under the national TB control program at that time. The ini-
tial result of Ziehl-Neelsen (ZN) staining of sputum was posi-
tive for acid-fast bacilli (AFB). Culture isolation and the drug
susceptibility tests were performed using BACTEC-MGIT 960
(BDTM), as per the World Health Organization (WHO) guide-
lines. The culture was identified as MTB by conventional phe-
notypic characteristics and confirmed by an in-house PCR
method [8]. The patient was administered free anti-tubercular
treatment (ATT) under the DOTS program of the Government
of India. (Please see methods). Three more culture isolations
were made during the course of the treatment period, albeit
at irregular intervals, and these sequential isolates were la-
Fig. 1 – Characterization of isolates, drug resistance patterns and gene mutations. Sputum specimens from a patient with
pulmonary tuberculosis were cultured before and during the anti-TB therapy. All the four isolates were identified as M.
tuberculosis. The initial isolate (A) was sensitive to all four first-line drugs (STR, INH, RIF and EMB) and later isolates (B, C and
D) acquired resistance to INH, RIF, and EMB with mutations in katG, inhA, rpoB and embB alleles. Isolate C and isolate D
acquired resistance to kanamycin (KAN) also, but remained sensitive to ofloxacin (OFL), ciprofloxacin (CIPRO) and para-
aminosalicylic acid (PAS) during the course of treatment. The spoligotype of all sequential isolates from patients were
identical. Abbreviations and explanations: H (Isoniazid), R (Rifampicin), Z (Pyrazinamide), E (Ethambutol), S (Streptomycin).
katG315 (G-C), katG463 (T-G), InhA-15 (C-T) and rpoB531 (C-T), rpoB531 (T-C), embB294 (G-A). eis promoter region and rrs gene have
no mutation.
38 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 3 6 –4 0beled as isolates A, B, C & D, respectively, as mentioned in the
material and methods section (Fig. 1).
The initial isolate (A) was sensitive to all of the four first-
line drugs (STR, INH, RIF and EMB), but the consecutive iso-
lates (isolates B, C and D) were found to be resistant to these
drugs. The MIC of isolate B increased significantly to INH, RIF
and EMB, however it was still sensitive to kanamycin. Signif-
icantly, the third and fourth isolates were found to be resis-
tant not only to INH, RIF and EMB, but also to kanamycin
(Fig. 1). Infection with multiple strains or re-infection with
other resistant strains during the course of treatment is com-
mon in endemic countries like India; hence, to confirm the
clonal nature of all the four isolates, spoligotyping was done,
and the results confirmed that all the isolates belonged to the
family of Central Asian Strain Delhi (CAS1_Delhi, ST26) geno-
type in the SITVITWEB database. The 24-loci MIRU-VNTR pat-
terns for all four isolates were identical and confirmed that all
isolates belonged to the same family with identical MIRU-
VNTR profiles (Fig. 1). The sequencing of the rpoB (RIFr), katG,
inhA (INHr), rrs and eis promoter regions (Kanr) revealed mu-
tated alleles associated with resistance to the INH, RIF, andEMB, but no mutation was found for kanamycin resistance,
as shown in Fig. 1. For INH resistance, katG 315 G-C, katG463
T-G and inhA-15 T-C were highly discernible between the
baseline isolate and sequential isolates. Similarly, RIF resis-
tance mutations were obvious in the second isolate
(rpoB531C-T, but not for rpoB533T-C), but third and fourth iso-
lates showed mutations in both alleles. To screen for EMB
resistance associated mutations, ERDR region was also stud-
ied and embB294 (G-A) mutation in resistant isolates was
found, i.e., second (B), third (C) and fourth (D) isolates, but
not in baseline isolate (A).
The worldwide distribution of ST26 strains was essentially
confined to the Middle East and Central Asia, more specifi-
cally in the Indian subcontinent (75%) [3,4]. Hence as ex-
pected, the isolates also belonged to this most prevalent
genotype.
There are only a few studies where differential MIC pattern
and genetic mutations have been reported in drug-sensitive
and drug-resistant isolates. Even these studies have been car-
ried out on isolates obtained from different patients [19,20].
Such isolates, therefore, do not provide deeper insight into
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MTB under in vivo conditions. Only recently, Saunders et al.
[21] reported a similar case in which they could isolate
sequential isolates from a patient on anti-tubercular treat-
ment, but their strategy of comparing sensitive and resistant
isolates was different from the one used in this study. They
only did deep sequencing of the isolates and found known
mutations in katG and rpoB genes. Another study was pub-
lished in 2012 from China [22]. In this study, the authors did
whole genome sequencing of seven sequential isolates from
three patients. The authors focused on the mixed diverse
populations of MTB strains in clinical samples and on the
selection of the most fit resistant strain in treatment failure
cases. Even though the patient in this study did not show
any mixed population at any stage, such instances are com-
mon but not frequently feasible to study. It is obvious from
the case history of our patient that the mycobacteria re-
mained under a constant intermittent drug pressure, which
is considered to be the most suitable condition for selection
of resistant strains in vivo [22]. However, the most interesting
finding in this case is resistance selection for 4 drugs within
27 months. This is alarmingly the fastest selection process
to best of this research’s knowledge. The speed at which the
strain turned from pan-sensitive to multidrug resistant is
highly disturbing for TB control programs and indicates that
more personalized counselling and awareness of strict adher-
ence to the regular drug regimens cannot be compromised.
This case also emphasizes the urgent need for compulsory
isolations and forced treatment in such non-cooperative pa-
tients to contain the fast spread of MDR-TB.Author contribution
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